We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Novel Drug Protects Against Heart Attack and Stroke

By Biotechdaily staff writers
Posted on 06 Feb 2008
A trans-Atlantic partnership will work towards wrapping up the development of a drug designed to prevent cardiac ischemia and stroke by being both cardio-protective and neuro-protective.

Myocardial ischemia, which can be silent or symptomatic, is an intermediate condition in coronary artery disease during which the heart tissue is slowly or is suddenly starved of oxygen and other nutrients. More...
Eventually, the affected heart tissue will die. When blood flow is completely blocked to the heart, ischemia can lead to a heart attack. Ischemia can also occur in the arteries of the brain, where blockages can lead to a stroke. About 80-85% of all strokes are ischemic. Most blockages in the cerebral arteries are due to a blood clot, often in an artery narrowed by plaque.

The drug under investigation is QGC002, a novel recombinant protein that acts to protect against both myocardial ischemia and stroke. The drug was discovered by investigators at the French Institut National de la Santé et de la Recherche Médicale (INSERM), and their partner, Quantum Genomics Corp. (Jersey City, NJ, USA), will fund and conduct pre-clinical development and drug manufacturing. Investigators at Inserm will perform pharmacologic studies in relevant animal models of the targeted diseases.

"This partnership with Inserm provides QGC with a novel first-in-class drug that complements our pipeline,” said Mr. Lionel Ségard, CEO of Quantum Genomics. "It contributes further to enhance our ambition to provide innovative products to treat diseases with significant unmet medical needs.”

"This partnership with Quantum Genomics Corporation gives us a great opportunity to participate in the development of a novel biotherapy,” said Dr. Brigitte Onteniente, senior investigator at INSERM.


Related Links:
INSERM
Quantum Genomics Corporation

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.